



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated March 26, 2018

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES; BSE: 532482

Sub: Granules India's Gagillapur and Jeedimetla facilities completed US FDA inspection.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Please be informed that, Company's Gagillapur and Jeedimetla facilities located at Hyderabad, Telangana, India has completed the US FDA inspection from 19th March 2018 to 23rd March 2018 without any 483 observations for Gagillapur facility and with 1 (one) 483 observation for Jeedimetla facility. Company will respond to this observation within the stipulated time period.



Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) whereas Jeedimetla facility manufactures Active pharmaceutical ingredients (APIs) and Pharmaceutical Formulation Intermediates (PFIs).

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

For **GRANULES INDIA LIMITED**



CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)